Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation

Dose-response studies

E. L C Pritchett, S. D. DaTorre, M. L. Platt, S. E. McCarville, A. J. Hougham, G. N. Kay, V. J. Plumb, A. E. Epstein, R. S. Bubien, A. K. Bhandari, A. M. Brinkley, B. L. Rosin, E. McCabe, J. J. Heger, W. M. Miles, L. S. Klein, D. P. Zipes, L. Crouter, T. Guarnieri

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2). Recurrent symptomatic tachycardia was documented with use of transtelephonic electrocardiographic recording. Patients received flecainide in doses of 25, 50, 100 and 150 mg twice daily and placebo for 1 month treatment periods. Among 14 patients in Group I who qualified for efficacy analysis, 4 (29%) had no tachycardia while taking placebo. The number with no tachycardia increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 12 (86%) of 14 patients had no tachycardia (p <0.01 for overall differences among all treatments). Among 28 patients in Group 2, 2 (7%) had no tachycardia while taking placebo. The number with no tachycardia also increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 17 (61%) of 28 patients had no tachycardia (p <0.01 for overall differences among all treatments). Noncardiac adverse experiences were the leading cause of premature study discontinuation during flecainide treatment periods (five patients in Group 1 and six patients in Group 2).

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalJournal of the American College of Cardiology
Volume17
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Flecainide
Paroxysmal Tachycardia
Supraventricular Tachycardia
Atrial Fibrillation
Tachycardia
Therapeutics
Placebos
Atrial Flutter
Anti-Arrhythmia Agents

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Pritchett, E. L. C., DaTorre, S. D., Platt, M. L., McCarville, S. E., Hougham, A. J., Kay, G. N., ... Guarnieri, T. (1991). Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies. Journal of the American College of Cardiology, 17(2), 297-303.

Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation : Dose-response studies. / Pritchett, E. L C; DaTorre, S. D.; Platt, M. L.; McCarville, S. E.; Hougham, A. J.; Kay, G. N.; Plumb, V. J.; Epstein, A. E.; Bubien, R. S.; Bhandari, A. K.; Brinkley, A. M.; Rosin, B. L.; McCabe, E.; Heger, J. J.; Miles, W. M.; Klein, L. S.; Zipes, D. P.; Crouter, L.; Guarnieri, T.

In: Journal of the American College of Cardiology, Vol. 17, No. 2, 1991, p. 297-303.

Research output: Contribution to journalArticle

Pritchett, ELC, DaTorre, SD, Platt, ML, McCarville, SE, Hougham, AJ, Kay, GN, Plumb, VJ, Epstein, AE, Bubien, RS, Bhandari, AK, Brinkley, AM, Rosin, BL, McCabe, E, Heger, JJ, Miles, WM, Klein, LS, Zipes, DP, Crouter, L & Guarnieri, T 1991, 'Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies', Journal of the American College of Cardiology, vol. 17, no. 2, pp. 297-303.
Pritchett, E. L C ; DaTorre, S. D. ; Platt, M. L. ; McCarville, S. E. ; Hougham, A. J. ; Kay, G. N. ; Plumb, V. J. ; Epstein, A. E. ; Bubien, R. S. ; Bhandari, A. K. ; Brinkley, A. M. ; Rosin, B. L. ; McCabe, E. ; Heger, J. J. ; Miles, W. M. ; Klein, L. S. ; Zipes, D. P. ; Crouter, L. ; Guarnieri, T. / Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation : Dose-response studies. In: Journal of the American College of Cardiology. 1991 ; Vol. 17, No. 2. pp. 297-303.
@article{c41f47d9ba324387bfc1bc479b391277,
title = "Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies",
abstract = "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2). Recurrent symptomatic tachycardia was documented with use of transtelephonic electrocardiographic recording. Patients received flecainide in doses of 25, 50, 100 and 150 mg twice daily and placebo for 1 month treatment periods. Among 14 patients in Group I who qualified for efficacy analysis, 4 (29{\%}) had no tachycardia while taking placebo. The number with no tachycardia increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 12 (86{\%}) of 14 patients had no tachycardia (p <0.01 for overall differences among all treatments). Among 28 patients in Group 2, 2 (7{\%}) had no tachycardia while taking placebo. The number with no tachycardia also increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 17 (61{\%}) of 28 patients had no tachycardia (p <0.01 for overall differences among all treatments). Noncardiac adverse experiences were the leading cause of premature study discontinuation during flecainide treatment periods (five patients in Group 1 and six patients in Group 2).",
author = "Pritchett, {E. L C} and DaTorre, {S. D.} and Platt, {M. L.} and McCarville, {S. E.} and Hougham, {A. J.} and Kay, {G. N.} and Plumb, {V. J.} and Epstein, {A. E.} and Bubien, {R. S.} and Bhandari, {A. K.} and Brinkley, {A. M.} and Rosin, {B. L.} and E. McCabe and Heger, {J. J.} and Miles, {W. M.} and Klein, {L. S.} and Zipes, {D. P.} and L. Crouter and T. Guarnieri",
year = "1991",
language = "English (US)",
volume = "17",
pages = "297--303",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation

T2 - Dose-response studies

AU - Pritchett, E. L C

AU - DaTorre, S. D.

AU - Platt, M. L.

AU - McCarville, S. E.

AU - Hougham, A. J.

AU - Kay, G. N.

AU - Plumb, V. J.

AU - Epstein, A. E.

AU - Bubien, R. S.

AU - Bhandari, A. K.

AU - Brinkley, A. M.

AU - Rosin, B. L.

AU - McCabe, E.

AU - Heger, J. J.

AU - Miles, W. M.

AU - Klein, L. S.

AU - Zipes, D. P.

AU - Crouter, L.

AU - Guarnieri, T.

PY - 1991

Y1 - 1991

N2 - The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2). Recurrent symptomatic tachycardia was documented with use of transtelephonic electrocardiographic recording. Patients received flecainide in doses of 25, 50, 100 and 150 mg twice daily and placebo for 1 month treatment periods. Among 14 patients in Group I who qualified for efficacy analysis, 4 (29%) had no tachycardia while taking placebo. The number with no tachycardia increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 12 (86%) of 14 patients had no tachycardia (p <0.01 for overall differences among all treatments). Among 28 patients in Group 2, 2 (7%) had no tachycardia while taking placebo. The number with no tachycardia also increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 17 (61%) of 28 patients had no tachycardia (p <0.01 for overall differences among all treatments). Noncardiac adverse experiences were the leading cause of premature study discontinuation during flecainide treatment periods (five patients in Group 1 and six patients in Group 2).

AB - The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2). Recurrent symptomatic tachycardia was documented with use of transtelephonic electrocardiographic recording. Patients received flecainide in doses of 25, 50, 100 and 150 mg twice daily and placebo for 1 month treatment periods. Among 14 patients in Group I who qualified for efficacy analysis, 4 (29%) had no tachycardia while taking placebo. The number with no tachycardia increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 12 (86%) of 14 patients had no tachycardia (p <0.01 for overall differences among all treatments). Among 28 patients in Group 2, 2 (7%) had no tachycardia while taking placebo. The number with no tachycardia also increased with progressively larger flecainide doses; with the 150 mg twice daily dose, 17 (61%) of 28 patients had no tachycardia (p <0.01 for overall differences among all treatments). Noncardiac adverse experiences were the leading cause of premature study discontinuation during flecainide treatment periods (five patients in Group 1 and six patients in Group 2).

UR - http://www.scopus.com/inward/record.url?scp=0025730751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025730751&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 297

EP - 303

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -